The head of Rospotrebnadzor Anna Popova said that preclinical studies of the vaccine from COVID-19 in the center "Vector" was completed July 15, is scheduled to begin testing on volunteers.
"Colleagues have done preclinical studies. They were successful. And we almost have every reason to be confident that it will, as we promised, July 15, we expect to enter the clinic," she said in an interview Naila Asker-zade, the TV channel "Russia 1", in response to a question.
Clinical studies of the vaccine against coronavirus in the center "Vector" will start with a group of 10 people aged 18 to 30 years, and later in the study will involve volunteers under the age of 60 years, said in an interview with RIA Novosti Director of the center for Rinat Maksyutov.
He noted that the decision about vaccination for the population can be taken only after final confirmation of safety and efficacy of the vaccine, its registration.
Discovered a mutation of the coronavirus does not lead to significant changes in the properties COVID-19, reported the press service of Rospotrebnadzor.
Earlier the General Director of "Vector" Rinat Maksyutov in an interview with RIA Novosti reported that more than 100 strains of the novel coronavirus have already been identified in Russia after the appearance of the first patients in the country.
Three prototype vaccines against coronavirus infection was successfully tested, said the General Director of the center "Vector" Rinat Maksyutov.
He said that in the center several groups are working on vaccines of new generation, with more than 100 employees.
More than 100 strains of the novel coronavirus have already been identified in Russia after the appearance of the first patients in the country, said General Director of "Vector" Rinat Maksyutov.
"When patients in Russia, we have identified the strains of the coronavirus, they now have more than 100", - he said in an interview with RIA Novosti.